Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase

NCT02032173 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
31
Enrollment
INDUSTRY
Sponsor class

Stopped Study was prematurely discontinued as it was unethical to continue based on a change in ranibizumab (RFB) marketing authorization.

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals